Acute coronary syndrome (ACS) in younger patients presents distinctive epidemiological and clinical patterns when compared with older cohorts. Although traditionally viewed as a disease of older ...

Daiichi Sankyo and Lilly Announce TRILOGY ACS Results Regarding Effient® (Prasugrel) in Acute Coronary Syndrome UA/NSTEMI Patients to be Managed Medically without an Artery-Opening ProcedureStudy did ...

How are Non-ST segment elevation myocardial infarction (NSTEMI) and acute coronary syndrome (ACS) patients currently identified? ACS is currently identified through the use of ECGs pre-hospital and ...

INDIANAPOLIS and TOKYO, Aug. 26, 2012 /PRNewswire/ -- Daiichi Sankyo Company, Limited (TSE: 4568) and Eli Lilly and Company (NYSE: LLY) today announced data from the TRILOGY ACS study, a phase III ...

The news reporters obtained a quote from the research from Diagnostica Stago, "To describe the characteristics, frequency of P2Y12-associated complications, adherence and persistence to P2Y12 APT, and ...

Growing evidence suggests that serum cortisol levels are associated with increased cardiovascular mortality in patients with chronic heart failure. Growing evidence suggests that serum cortisol levels ...

A recent opinion paper concluded that timely revascularization and dual antiplatelet therapy (DAPT) are crucial in the ...

PARIS — In patients with suspected acute coronary syndrome (ACS), there was no difference in overall 30-day mortality between a high- and low-usage oxygen protocol in a new study involving the whole ...

Whether the reduced ischemic risk from adding a novel oral anticoagulant (NOAC) to antiplatelets in patients with acute coronary syndromes (ACS) is worth the increased hazard from major bleeding may ...

The number of UA or NSTEMI ACS patients worldwide who are managed without acute coronary interventions, such as PCI, has ranged from 32 percent to almost 60 percent over the last few years. (5,6) In ...